Clinical Trials Logo

Pulmonary Embolism clinical trials

View clinical trials related to Pulmonary Embolism.

Filter by:

NCT ID: NCT05028244 Recruiting - Covid19 Clinical Trials

Evaluation of Serial Ultrasound Screening in ICU COVID-19 Patients

Start date: June 15, 2021
Phase: N/A
Study type: Interventional

This clinical trial is destinated to evaluate if the periodic screening for deep venous thrombosis by ultrasound of lower extremity in patients with intensive care unit (ICU) patients with COVID 19 impacts on mortality, ICU stay and total lenght of stay in the hospital, along with other outcomes.

NCT ID: NCT05015153 Not yet recruiting - Pulmonary Embolism Clinical Trials

Impact on Quality of Life With Pulmonary RehAbilitation After Pulmonary eMBOlism: RAMBO Study

Start date: October 2021
Phase: N/A
Study type: Interventional

Pulmonary Embolism (PE) is a common and serious disease. Indeed, the annual incidence is 1/1000 patients per year and the 3-month mortality is 10%, which is twice that of myocardial infarction. The treatment is based on anticoagulation for at least 3 months. However, after three or six months of anticoagulation, persistent dyspnea and impairment of quality of life are observed in at least 30% of cases. Several mechanisms explain dyspnea and impairment of quality of life after PE, such as residual pulmonary artery obstruction, exercise deconditioning, depressive syndrome or development of a cardio-respiratory pathology. Pulmonary rehabilitation (PR) has been shown to be effective on dyspnea and quality of life and is included in the therapeutic management of chronic respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD) or pulmonary fibrosis. Furthermore, PR is also used after a myocardial infarction. However, PR after PE is still not included in therapeutic management of PE while outpatient management is recommended for the majority of patients after an acute PE episode. Study hypothesis is that PR has the potential to improve quality of life and dyspnea perception in patients who have received anticoagulation for at least 3 months after PE and who present an impairment of quality of life and/or a persistent dyspnea. This study presents several innovative aspects. First, to our knowledge, This study is the first large randomized trial assessing PR at least 3 months after acute symptomatic PE. Only one small randomized trial on 18 patients evaluating the impact of PR after PE has been published; as PR was performed just after the acute phase of PE in this trial, the clinical status improvement observed in this study could not be explained by PR alone, but also by anticoagulation. In this study, the investigators will include 112 patients at least 3 months after PE in order to exclude the bias related to anticoagulation effect. Second, This study is the first large randomized trial. Third, this study is the first that have the potential to demonstrate efficacy and safety of delayed PR after PE in patients with impaired quality of life due to persistent residual dyspnea.

NCT ID: NCT04996693 Not yet recruiting - Lung Cancer Clinical Trials

On Dose Efficiency of Modern CT-scanners in Chest Scans

Start date: August 10, 2021
Phase: N/A
Study type: Interventional

CT scans of the chest / thorax are of great importance both in the initial diagnosis and in the follow-up of pulmonary or thoracic diseases. As an example, CT angiography of the pulmonary arteries (CTPA) is worldwide considered to be gold standard test in patients with a suspicion for pulmonary embolism. The aim of this study is to measure and compare dose efficiency of modern CT scanners for unenhanced and contrast-enhanced scan protocols of the chest/thorax. Patients who are referred for a CT of the chest/thorax will be randomly assigned to one of the three CT scanners currently in use at our institution.

NCT ID: NCT04996667 Not yet recruiting - Pulmonary Embolism Clinical Trials

Effect of iNO in Patients With Submassive and Massive PE

Start date: September 7, 2021
Phase: Phase 2
Study type: Interventional

A single center study to evaluate the effect of inhaled nitric oxide (iNO) on pulmonary dynamics in patients presenting with imaging confirmed intermediate/submassive or massive pulmonary embolism (PE). The target enrollment is 20 subjects at Ronald Reagan UCLA Medical Center. PE patients undergoing catheter-based intervention will be administered iNO during their intervention and pulmonary hemodynamic measurement will be measured before, during, and after iNO administration (Invasive Cohort). Patients who are not undergoing catheter-based intervention will also be administered iNO and will have pulmonary hemodynamics, blood pressure, and heart rate measured non-invasively (Non-Invasive Cohort).

NCT ID: NCT04990505 Not yet recruiting - Clinical trials for SARS-CoV-2 Infection

Microvascular Injury and Distal Thrombosis in COVID-19

Start date: August 2021
Study type: Observational

Investigators aimed to better understand the pathophysiology of SARS-CoV-2 pneumonia in non-critically ill hospitalized patients secondarily presenting with clinical deterioration and increase in oxygen requirement

NCT ID: NCT04987008 Recruiting - Clinical trials for Foramen Ovale, Patent

Risk of Ischaemic Stroke After Pulmonary Embolism in Patients With and Without Patent Foramen Ovale

Start date: May 18, 2021
Study type: Observational

stroke's risk is increased in patients with pulmonary embolism and PFO compared to patients without PFO. Does this increased risk persist years after pulmonary embolism ?

NCT ID: NCT04980924 Recruiting - Pulmonary Embolism Clinical Trials

Epidemiology and Clinical Course of Pulmonary Embolism During and After Hospitalisation

Start date: January 1, 1992
Study type: Observational

This survey will allow to identify PE prognostic, but also long-term complications, i.e. recurrence rate, on-treatment bleedings, deep-vein thrombosis sequella, pulmonary hypertension rate, and chronic pulmonary disease rate without PH. This database should help us identify risk-factors for each event.

NCT ID: NCT04979780 Active, not recruiting - Clinical trials for Treatment of Deep Vein Thrombosis and/or Pulmonary Embolism in Cancer Patients

Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort

Start date: July 20, 2021
Study type: Observational

Patients with active cancer are ~5-fold more likely to develop a venous thromboembolism (VTE) than those without. When VTE occurs, cancer patients carry an up to a 3-fold higher rate of thrombosis recurrence and ~twice the risk of bleeding during anticoagulation. Therefore, it is critical to utilize anticoagulants that optimize efficacy while minimizing bleeding risk when treating cancer-associated thrombosis (CAT). Guidelines list direct-acting oral anticoagulants (DOACs) as an alternative to low molecular-weight heparin (LMWH) for treatment of CAT. The strength-of-recommendation for DOACs is based on data from multiple randomized controlled trials (RCTs) comparing them to LMWHs to treat CAT, with results suggesting DOACs may reduce thrombosis risk but with potentially more frequent bleeding (particularly in those with certain gastrointestinal and genitourinary cancers). Observational studies evaluating DOACs for CAT treatment have been published, but these studies have been either single-arm, evaluated cancer subtypes not recommended for DOAC treatment, were of limited sample size and/or employed heterogeneous definitions of active cancer. We seek to evaluate the effectiveness and safety of rivaroxaban versus LMWH for CAT treatment in active cancer patients using a large de-identified electronic health record database. Retrospective cohort analysis using US Optum® De-Identified EHR data. We will use Optum EHR (electronic health records) data from November January 1, 2012 through latest available data (currently September 2020).

NCT ID: NCT04969653 Active, not recruiting - Atopic Dermatitis Clinical Trials

The Incidence of Venous Thromboembolism in Atopic Dermatitis

Start date: June 21, 2021
Study type: Observational

This study aims to investigate the incidence of venous thromboembolism in people who are diagnosed with atopic dermatitis.

NCT ID: NCT04949048 Not yet recruiting - Pulmonary Embolism Clinical Trials

Evaluation of the Safety and Performance of Magneto PE Kit

Start date: July 2021
Phase: N/A
Study type: Interventional

This study is designed as a prospective, multi-center, multinational open labeled, single armed study to evaluate the safety and performance of the Magneto PE Kit.